Narvalus

Narvalus is a South San Francisco-based biotechnology company focused on the discovery and development of novel therapeutics for neurodegenerative disorders. Led by former executives from Alector and Genentech, the company specializes in neuro-immunology, specifically targeting pathways that regulate microglial activity and neuroinflammation. Narvalus aims to address the high unmet medical need in conditions like Alzheimer's disease by modulating the brain's innate immune system. The company is currently advancing its proprietary platform through pre-clinical research supported by leading life science investors. By focusing on the intersection of immunology and neurology, Narvalus seeks to develop disease-modifying treatments that can slow or halt the progression of devastating brain diseases.